BioNTech SE ( (BNTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
BioNTech SE’s stock price dropped after the company released its Q4 2024 earnings report. Despite surpassing EPS and revenue estimates, the shares fell due to a net loss of €0.7 billion, attributed to declining COVID-19 vaccine sales and Pfizer’s write-downs. The company’s 2025 revenue guidance of €1.7 billion to €2.2 billion was lower than expected, disappointing investors. Analysts remain cautious, citing stable vaccination rates and uncertainties in the oncology pipeline. BofA reduced BioNTech’s price target, though it remains optimistic about the company’s strategic focus on oncology. The stock is expected to remain volatile, with options activity hinting at potential earnings fluctuations.
More about BioNTech SE
YTD Price Performance: -8.63%
Average Trading Volume: 743,844
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $25.26B
For further insights into BNTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.
Questions or Comments about the article? Write to editor@tipranks.com